The Minocycline, the good, the bad, and the ugly
 

 

Home Page

About Dermagic

Contact Dermagic

Next Edition

Past Editions

Secret X files 

 

 

The Minocycline, the good, the bad, and the ugly.

La minociclina, lo bueno, lo malo y lo feo.


************************************
****** DATA-MÉDICOS **********
************************************ 
LA MINOCICLINA: LO BUENO LO MALO Y LO FEO
THE MINOCYCLINE: THE GOOD, THE BAD, AND THE UGLY.
**************************************
****** DERMAGIC-EXPRESS No.42 ******* 
****** 17 MARZO DE 1.999 ********* 
17 MARCH 1.999
**************************************




EDITORIAL ESPAÑOL:
=====================
Hola amigos DERMAGICOS, el tema de hoy LA MINOCICLINA, lo bueno la malo y feo de este antibiótico.

Quien iba a pensar hace unos años, que este popular medicamento iba a tener efectos beneficiosos sobre enfermedades como la lepra, esclerodermia, pénfigo, pioderma gangrenoso, penfigoide, papilomatosis reticulada y otras más.

Estas 49 referencias nos ilustran bien el tema. 

Y les pregunto,, realmente la Minociclina se esta usando en la lepra en nuestros países, ??? 

Dras.: Ana Rita y María Alejandra Jiménez (Venezuela), bienvenidas a DERMAGIC 

Próxima edición: Colagenosis: LA MORFEA 

Saludos a TODOS,,, 

Dr. José Lapenta R.,,,

EDITORIAL ENGLISH:
=====================
Hello DERMAGICS, friends the topic of today THE MINOCICLINA, the good thing the bad and ugly of this antibiotic.

Who will have thought for some years that this popular medication will have beneficial effects on illnesses like the leprosy, scleroderma, pemphigus, gangrenous pyoderma, pemphigoid, reticulated papillomatosis and other but.

This 49 references illustrate us well the topic. 

And do I ask you, really the Minocycline is it using in the leprosy in our countries??? 

Dras.: Ana Rita and María Alejandra Jiménez (Venezuela), welcome to DERMAGIC 

Next edition: THE MORPHEA (LOCALIZED SCLERODERMA).

Greetings to ALL, 

Dr. José Lapenta R.,,,



================================================================
DERMAGIC/EXPRESS(42)
================================================================
MINOCICLINA, LO BUEN LO MALO Y LO FEO / MINOCYCLINE, THE GOOD, THE BAD, AND THE UGLY 
================================================================
======================================================================
()()()()()()()()()()()() LO BUENO  / THE GOOD ()()()()()()()()()()()()()() 
=========================================================================
1.) Superior antibacterial action and reduced incidence of bacterial resistance in minocycline compared to tetracycline-treated acne patients. 
2.) Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline, but sensitive to minocycline. 
3.) Research letters : Minocycline in early diffuse scleroderma
4.) Minocycline in lepromatous leprosy. 
5.) Efficacy of minocycline in single dose and at 100 mg twice daily for lepromatous leprosy. 
6.) Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results. 
7.) Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. 
8.) Efficacy of single dose multidrug therapy for the treatment of single-lesion paucibacillary leprosy. Single-lesion Multicentre Trial Group. 
9.) Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. 
10.) WHO Expert Committee on Leprosy. 
11.) Experimental evaluation of possible new short-term drug regimens for treatment of multibacillary leprosy. 
12.) Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. 
13.) Minocycline is a useful adjuvant therapy for pemphigus. 
14.) Confluent and reticulated papillomatosis: response to minocycline. 
15.) Minocycline treatment for confluent and reticulated papillomatosis. 
16.) No detection of Borrelia burgdorferi-specific DNA in erythema migrans lesions after minocycline treatment. 
17.) Minimizing cicatricial pemphigoid orodynia with minocycline. 
18.) Response of atypical bullous pyoderma gangrenosum to oral minocycline hydrochloride and topical steroids. 
19.) Blastomycosis-like pyoderma--report of a case responsive to combination therapy utilizing minocycline and carbon dioxide laser debridement. 
20.) A sporotrichoid-like Mycobacterium kansasii infection of the skin treated with minocycline hydrochloride. 
21.) Primary lymphocutaneous nocardiosis due to Nocardia otitidiscaviarum: the first case report from Japan. 
22.) Minocycline treatment of pulmonary nocardiosis. 
23.) Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group [see comments] 
24.) Minocycline prevents the decrease in bone mineral density and trabecular bone in ovariectomized aged rats. 
25.) Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection. 
26.) The role of minocycline in the treatment of intracranial 9L glioma. 
27.) Evaluation of the long-term efficacy and safety of locally-applied minocycline in adult periodontitis patients. 
28.) Clinical and microbiological effects of minocycline-loaded microcapsules in adult periodontitis. 
29.) The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampin. 
30.) Symptomatic hepatic cysts: treatment with single-shot injection of minocycline hydrochloride. 
======================================================================
()()()(()()()()()()()()( LO MALO / THE BAD ()()()()()()()()()()()()()()
======================================================================
31.) Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome [see comments] 
32.) Minocycline and Lupuslike Syndrome in Acne Patients 
33.) Minocycline-induced lupus. 
34.) Minocycline related lupus. 
35.) Acute hepatitis and drug-related lupus induced by minocycline treatment. 
36.) Minocycline-induced pneumonitis with bilateral hilar lymphadenopathy and pleural effusion. 
37.) Comparative safety of tetracycline, minocycline, and doxycycline. 
38.) Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. 
39.) [Side effects of minocycline in the treatment of acne vulgaris] 
40.) Serious dermatologic reactions in children. 
41.) Serum sickness-like syndrome associated with minocycline therapy. 
42.) Minocycline-induced loss of potassium from erythrocytes: identification of a family with an augmented response. 
======================================================================
()()()()()()()()()()()()()() LO FEO / THE UGLY ()()()()()()()()()()()()
======================================================================
43.) Minocycline-induced hyperpigmentation in leprosy. 
44.) Psoriatic arthritis and minocycline induced autoantibodies.
45.) Minocycline hydrochloride hyperpigmentation complicating treatment of
pyoderma gangrenosum. 
46.) Minocycline-induced oral pigmentation. 
47.) Nodular hyperplasia, black thyroid, and chronic minocycline ingestion
in a teenager. 
48.) Black bones following long-term minocycline treatment. 
49.) Pigmented postacne osteoma cutis in a patient treated with
minocycline: report and review of the literature. 
======================================================================
======================================================================
()()()()()()()()()()()() LO BUENO  / THE GOOD ()()()()()()()()()()()()()()

======================================================================
======================================================================
1.) Superior antibacterial action and reduced incidence of bacterial resistance in minocycline compared to tetracycline-treated acne patients. 
=========================================================================
ARTICLE SOURCE: Br J Dermatol (England), Feb 1990, 122(2) p233-44 
AUTHOR(S): Eady EA; Cove JH; Holland KT; Cunliffe WJ 
PUBLICATION TYPE: JOURNAL ARTICLE 

ABSTRACT: Twenty-five previously untreated acne patients were monitored throughout a 6-month course of therapy with either tetracycline or minocycline for changes in the numbers of staphylococci, propionibacteria and yeasts of the genus Malessezia on the skin surface. Antibiotic resistant staphylococci and propionibacteria were also counted. Minocycline (50 mg b.d.) produced a 10-fold greater reduction in propionibacterial numbers compared to tetracycline (500 mg b.d.) after 12 (P less than 0.02, t-test) and 24 weeks (P less than 0.05) of therapy. As treatment progressed, propionibacteria were replaced by yeasts, numbers of which were significantly increased by week 12 (P less than 0.02) in tetracycline-treated patients and by week 24 (P less than 0.01) in minocycline-treated patients.

This suggests that yeasts have no role in the pathogenesis of acne but may compete with propionibacteria for the same niche. Overgrowth of antibiotic resistant staphylococci prevented any decrease in staphylococcal numbers in tetracycline-treated patients, but minocycline produced a significant and sustained reduction in staphylococcal numbers after 1 week of therapy (P less than 0.001).

An increase in the number of multiply resistant (greater than or equal to 3 resistances) staphylococci occurred in 67% of tetracycline-treated and 33% of minocycline-treated patients by the end of the treatment period. There was no evidence of propionibacterial resistance in either treatment group. This study shows that minocycline has much greater antibacterial activity in vivo against both staphylococci and propionibacteria and produces less staphylococcal antibiotic resistance than tetracycline. 

=========================================================================
2.) Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline, but sensitive to minocycline. 
=========================================================================
ARTICLE SOURCE: Br J Dermatol (England), May 1993, 128(5) p556-60 
AUTHOR(S): Eady EA; Jones CE; Gardner KJ; Taylor JP; Cove JH; Cunliffe WJ 
PUBLICATION TYPE: JOURNAL ARTICLE 

ABSTRACT: Antibiotic-resistant propionibacteria are being isolated with increasing frequency from antibiotic-treated acne patients. Minimum inhibitory concentrations (MICs) of three tetracyclines, extensively used in acne therapy, were determined for 46 resistant and 19 sensitive propionibacteria isolates. Sensitive strains were inhibited by or = 1 microgram/ml of all three tetracyclines. For every resistant strain tested, the MIC of tetracycline exceeded that of doxycycline which, in turn, exceeded that of minocycline.

The mean MIC for resistant strains was 20.61 +/- 4.56 micrograms/ml of tetracycline, 9.70 +/- 2.03 micrograms/ml of doxycycline and 1.95 +/- 0.35 micrograms/ml of minocycline. In order to determine whether these strains could be inhibited by concentrations of minocycline achievable in vivo, serum levels of minocycline were determined in acne patients receiving either the recommended dose of 50 mg b.d. (20 males, 14 females), or twice this dose (21 males, 12 females). Serum levels were significantly higher (P 0.001, Student's t-test) in patients receiving 100 mg b.d. Males on 50 mg b.d. had significantly lower serum levels than females on the same dose (P 0.05. Student's t-test). For all patients, the mean serum level on high-dose minocycline was 2.46 +/- 0.45 micrograms/ml, compared with 1.38 +/- 0.30 micrograms/ml on the smaller dose.

These results indicate that tetracycline-resistant propionibacteria should be considered clinically minocycline sensitive, if patients who harbour such strains are prescribed 100 mg b.d. The recommended dose of minocycline for treating acne, especially in male patients, should be re-assessed. 

=========================================================================
3.) Research letters : Minocycline in early diffuse scleroderma
=========================================================================
The Lancet 1998;352(9142):1755-6

Minocycline may effectively treatearly diffuse scleroderma. 11 patients in the early stages of skin disease treated in open-label fashion for up to one year with minocycline. Six patients completed the study, of whom four had complete resolution of disease. 

=========================================================================
4.) Minocycline in lepromatous leprosy. 
=========================================================================
Author 
Fajardo TT Jr; Villahermosa LG; dela Cruz EC; Abalos RM; Franzblau SG; Walsh GP 
Address 
Clinical Research Branch, Leonard Wood Memorial Center, Cebu City, The Philippines. 
Source 
Int J Lepr Other Mycobact Dis, 63(1):8-17 1995 Mar 

Abstract 

Twelve patients were treated with three dose levels of minocycline for 30 days, primarily to detect the dose-related effects on Mycobacterium leprae viability, followed by another 5 months of daily minocycline for overall efficacy and persistence of clinical and antibacterial effects. Subsequently, the patients were given standard WHO/MDT chemotherapy for multibacillary leprosy.

Clinical improvement was recognizable during the first month, occurring much earlier among those on minocycline 200 mg daily than those who received minocycline 100 mg daily. A similar change also was observed in one patient 11 days after three daily doses of 100 mg of minocycline. At the end of 6 months, all patients were clinically improved with a slight reduction in the average bacterial index (BI) and logarithmic index of bacilli in biopsy (LIB). The effects of minocycline on viability by mouse foot pad inoculation and palmitic acid oxidation assays were noted beginning at 10 to 14 days of daily dosing and becoming more definite after 30 days of treatment. Both tests correlated fairly well.

Doses of 200 mg daily did not appear to be more efficient than minocycline 100 daily. Phenolic glycolipid-I (PGL-I) antigen determinations done on some patients during the first month remained positive and did not correlate with changes in viability results. At the end of 6 months, after 5 months of 100 mg of minocycline monotherapy, no viable organisms could be demonstrated by mouse foot pad inoculation and palmitic acid oxidation assays; assays for PGL-I antigen were all negative.(ABSTRACT TRUNCATED AT 250 WORDS) 

=========================================================================
5.) Efficacy of minocycline in single dose and at 100 mg twice daily for lepromatous leprosy. 
=========================================================================
Int J Lepr Other Mycobact Dis (United States), Dec 1994, 62(4) p568-73 
AUTHOR(S): Gelber RH; Murray LP; Siu P; Tsang M; Rea TH 
AUTHOR'S ADDRESS: San Francisco Regional Hansen's Disease Program, CA 94115. 
PUBLICATION TYPE: CLINICAL TRIAL; JOURNAL ARTICLE 

ABSTRACT: A clinical trial of minocycline in a total of 10 patients with previously untreated lepromatous leprosy was conducted in order to evaluate the efficacy of a single, initial, 200-mg dose and 100 mg twice daily of minocycline for a total duration of up to 3 months.

Patients improved remarkably quickly. Although single-dose therapy did not result in a significant killing of Mycobacterium leprae, viable M. leprae were cleared from the dermis regularly by 3 months of twice-daily therapy, a rate similar to that achieved by minocycline 100 mg once daily. Because more side effects were noted herein than previously with 100 mg daily, we recommend that minocycline, when applied, be administered at 100 mg daily to leprosy patients. 

=========================================================================
6.) Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results. 
=========================================================================
Author 
Mane I; Cartel JL; Grosset JH 
Address 
Institut de Leprologie Appliquee, Dakar CD Annexe, Senegal. 
Source 
Int J Lepr Other Mycobact Dis, 65(2):224-9 1997 Jun 

Abstract 

In 1995, a field trial was implemented in Senegal in order to evaluate the efficacy of a regimen based on the monthly supervised intake of rifampin 600 mg, ofloxacin 400 mg and minocycline 100 mg to treat leprosy. During the first year of the trial, 220 patients with active leprosy (newly detected or relapsing after dapsone monotherapy) were recruited: 102 paucibacillary (PB) (60 males and 42 females) and 118 multibacillary (MB) (71 males and 47 females). All of them accepted the new treatment (none requested to be preferably put under standard WHO/MDT), no clinical sign which could be considered as a toxic effect of the drug was noted, and none of the patients refused to continue treatment because of any clinical trouble.

The compliance was excellent: the 113 patients (PB and MB) detected during the first 6 months of the trial have taken six monthly doses in 6 months, as planned. The rate of clearance and the progressive decrease of cutaneous lesions was satisfactory. Although it is too soon to give comprehensive results, it should be noted that no treatment failure was observed in the 56 PB patients who have completed treatment and have been followed up for 6 months.

The long-term efficacy of the new regimen is to be evaluated on the rate of relapse during the years following the cessation of treatment. If that relapse rate is acceptable (similar to that observed in patients after treatment with current standard WHO/ MDT), the new regimen could be a solution to treat, for instance, patients very irregular and/or living in remote or inaccessible areas since no selection of rifampin-resistant Mycobacterium leprae should be possible (a monthly dose of ofloxacin and minocycline being as effective as a dose of dapsone and clofazimine taken daily for 1 month).

Nevertheless, until longer term results of this and other trials become available, there is no justification for any change in the treatment strategy, and all leprosy patients should be put under standard WHO/MDT. 

=========================================================================
7.) Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. 
=========================================================================
Author 
Ji B; Sow S; Perani E; Lienhardt C; Diderot V; Grosset J 
Address 
Facult´e de M´edecine Piti´e-Salp^etri`ere, Paris, France. [email protected] 
Source 
Antimicrob Agents Chemother, 42(5):1115-20 1998 May 

Abstract 

To develop a fully supervisable, monthly administered regimen for treatment of leprosy, the bactericidal effect of a single-dose combination of ofloxacin (OFLO) and minocycline (MINO), with or without rifampin (RMP), against Mycobacterium leprae was studied in the mouse footpad system and in previously untreated lepromatous leprosy patients. Bactericidal activity was measured by the proportional bactericidal method. In mouse experiments, the activity of a single dose of the combination OFLO-MINO was dosage related; the higher dosage of the combination displayed bactericidal activity which was significantly inferior to that of a single dose of RMP, whereas the lower dosage did not exhibit a bactericidal effect.

In the clinical trial, 20 patients with previously untreated lepromatous leprosy were treated with a single dose consisting of either 600 mg of RMP plus 400 mg of OFLO and 100 mg of MINO or 400 mg of OFLO plus 100 mg of MINO. The OFLO-MINO combination exhibited definite bactericidal activity in 7 of 10 patients but was less bactericidal than the RMP-OFLO-MINO combination. Both combinations were well tolerated.

Because of these promising results, a test of the efficacy of multiple doses of ROM in a larger clinical trial appears justified. 

=========================================================================
8.) Efficacy of single dose multidrug therapy for the treatment of single-lesion paucibacillary leprosy. Single-lesion Multicentre Trial Group. 
=========================================================================
Source 
Indian J Lepr, 69(2):121-9 1997 Apr-Jun 

Abstract 

A multicentre double-blind controlled clinical trial was carried out to compare the efficacy of a combination of rifampicin 600 mg plus ofloxacin 400 mg plus minocycline 100 mg (ROM) administered as single dose with that of the standard six-month WHO/MDT/PB regimen.

The subjects included 1483 cases with one skin lesion who were previously untreated, were smear-negative, and had no evidence of peripheral nerve trunk involvement, and they were randomly divided into study and control groups. The total duration of the study from the day of intake was 18 months, and 1381 patients completed study. Only 12 patients were categorized as treatment failure and no difference was observed between the two regimens. Occurrence of mild side-effects and leprosy reactions were minimal (less than 1%) in both groups.

This study showed that ROM is almost as effective as the standard WHO/MDT/PB in the treatment of single lesion PB leprosy. 

=========================================================================
9.) Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. 
=========================================================================
Author 
Ji B; Jamet P; Perani EG; Sow S; Lienhardt C; Petinon C; Grosset JH 
Address 
Facult´e de M´edecine Piti´e-Salp^etri`ere, Paris, France. 
Source 
Antimicrob Agents Chemother, 40(9):2137-41 1996 Sep 

Abstract 

Fifty patients with newly diagnosed lepromatous leprosy were allocated randomly to one of five groups and treated with either a month-long standard regimen of multidrug therapy (MDT) for multibacillary leprosy, a single dose of 600 mg of rifampin, a month-long regimen with the dapsone (DDS) and clofazimine (CLO) components of the standard MDT, or a single dose of 2,000 mg of clarithromycin (CLARI) plus 200 mg of minocycline (MINO), with or without the addition of 800 mg of ofloxacin (OFLO).

At the end of 1 month, clinical improvement accompanied by significant decreases of morphological indexes in skin smears was observed in about half of the patients of each group. A significant bactericidal effect was demonstrated in the great majority of patients in all five groups by inoculating the footpads of mice with organisms recovered from biopsy samples obtained before and after treatment.

Rifampin proved to be a bactericidal drug against Mycobacterium leprae more potent than any combination of the other drugs. A single dose of CLARI-MINO, with or without OFLO, displayed a degree of bactericidal activity similar to that of a regimen daily of doses of DDS-CLO for 1 month, suggesting that it may be possible to replace the DDS and CLO components of the MDT with a monthly dose of CLARI-MINO, with or without OFLO.

However, gastrointestinal adverse events were quite frequent among patients treated with CLARI-MINO, with or without OFLO, and may be attributed to the higher dosage of CLARI or MINO or to the combination of CLARI-MINO plus OFLO. In future trials, therefore, we propose to reduce the dosages of the drugs to 1,000 mg of CLARI, 100 mg of MINO, and 400 mg of OFLO. 

=========================================================================
10.) WHO Expert Committee on Leprosy. 
=========================================================================
Source: World Health Organ Tech Rep Ser, 874():1-43 1998 

Abstract 

Considerable progress has been made in the fight against leprosy during the past 10-15 years, following the introduction of multidrug therapy (MDT) regimens and the establishment of the goal of eliminating leprosy as a public health problem by the year 2000.

Current estimates indicate that there are about 1.15 million cases of leprosy in the world, compared with 10-12 million cases in the mid-1980s. This report presents the conclusions of a WHO Expert Committee convened to review the global leprosy situation and the technology available for eliminating the disease, to identify the remaining obstacles to reaching the goal of eliminating leprosy as a public health problem, and to make appropriate recommendations for the future on technical and operational matters.

The current status of leprosy elimination is discussed, and the various antileprosy drugs are reviewed, including the most recently available drugs. On the basis of field trials and clinical studies, the Committee concludes that a single dose of a combination of rifampicin, ofloxacin and minocycline is an acceptable and cost-effective alternative regimen for the treatment of single-lesion paucibacillary leprosy, and that the duration of the current MDT regimen for multibacillary leprosy could possibly be shortened to 12 months.

The Committee points out the need for improved management of reactions and neuritis and prevention of leprosy-related disabilities and impairments, and recommends that antileprosy activities should become an integral part of general health services and should involve communities to the fullest extent possible. 

=========================================================================
11.) Experimental evaluation of possible new short-term drug regimens for treatment of multibacillary leprosy. 
=========================================================================
Author 
Banerjee DK; McDermott-Lancaster RD; McKenzie S 
Address 
Department of Medical Microbiology, St George's Hospital Medical School, London, United Kingdom. [email protected]
Source 
Antimicrob Agents Chemother, 41(2):326-30 1997 Feb 

Abstract 

Groups of nude mice, with both hind footpads infected with 10(8) Mycobacterium leprae organisms, were treated with 4-week courses of different drug combinations. The effect treatment on each group was evaluated by subinoculating footpad homogenates from the treated mice into groups of normal and nude mice for subsequent regrowth, assessed 1 year later.

A combination of rifampin (RMP) with clarithromycin (CLARI), minocycline (MINO), and ofloxacin (OFLO) resulted in the complete killing of M. leprae after 3 weeks of treatment. A combination of sparfloxacin (SPAR) and RMP also resulted in a similar bactericidal effect after 3 weeks of treatment.

Other drug combinations showed variable effects. Very little or no effect was observed with any regimen if the treatment was given for less than 2 weeks. World Health Organization (WHO) multidrug therapy (MDT) given for 8 weeks was as effective as the two combinations described above.

The results suggest that multidrug combinations consisting of RMP-OFLO (or SPAR)-CLARI (and/or MINO) are as effective as the WHO MDT for the treatment of experimental leprosy. Moreover, they imply that these combinations, which were found to be active in a 4-week experimental treatment protocol, could be administered as treatment to patients for a period of time shorter than the present 2-year regimen without a loss of effectiveness. 

=========================================================================
12.) Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. 
=========================================================================
ARTICLE SOURCE: J Infect Dis (United States), Jul 1993, 168(1) p188-90 
AUTHOR(S): Ji B; Jamet P; Perani EG; Bobin P; Grosset JH 
AUTHOR'S ADDRESS: Faculte de Medecine Pitie-Salpetriere, Paris, France. 
PUBLICATION TYPE: CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL 

ABSTRACT: Thirty-six patients with newly diagnosed lepromatous leprosy were allocated randomly to three groups and treated for 56 days with minocycline (100 mg daily), clarithromycin (500 mg daily), or clarithromycin (500 mg) plus minocycline (100 mg daily). All groups had rapid and remarkable clinical improvement and significant decline of the bacterial and morphologic indices in skin smears during treatment.

More than 99% and 99.9% of the viable Mycobacterium leprae had been killed by 28 and 56 days of treatment, respectively, as measured by inoculation of organisms recovered from skin samples, taken before and during treatment, into the footpads of immunocompetent and nude mice.

Clinical improvement and bactericidal activity did not differ significantly among the three groups. Adverse reactions were rare and mild, and no laboratory abnormality was detected during the trial. Both clarithromycin and minocycline displayed powerful bactericidal activities against M. leprae in leprosy patients and may be considered important components of new multidrug regimens for the treatment of multibacillary leprosy. 

=========================================================================
13.) Minocycline is a useful adjuvant therapy for pemphigus. 
=========================================================================
Author 
Gaspar ZS; Walkden V; Wojnarowska F 
Address 
Department of Dermatology, Churchill, Oxford Radcliffe Hospital, Headington, UK. 
Source 
Australas J Dermatol, 37(2):93-5 1996 May 

Abstract 

Pemphigus is an autoimmune blistering disease with high mortality if untreated. The cases of 10 patients who had minocycline 100 mg daily added as adjuvant therapy are reported. Prior to the use of minocycline, all patients had active disease, nine were on prednisolone (10-40 mg) and five were on azathioprine (100-200 mg). The response was assessed on clinical improvement and reduction of immunosuppressive (IS) drugs. It was graded into four categories: major, minor, equivocal and no significant response.

A major response was seen in four patients, minor in two, equivocal in one and no improvement in three patients. The prednisolone dose in the six responders was reduced to 0-6 mg (0 mg in three patients), with an average decrease of 21 mg. The average time to respond was 8 months.

Of the six responders, three were on azathioprine, which was ceased in two patients and reduced by two-thirds in the other patient. No patient ceased minocycline because of side effects. In conclusion, minocycline 100 mg daily is a simple, safe and well tolerated treatment that should be tried in patients with pemphigus to reduce disease activity and/or the dose of potent IS agents. 

=========================================================================
14.) Confluent and reticulated papillomatosis: response to minocycline. 
=========================================================================
Author 
Montemarano AD; Hengge M; Sau P; Welch M 
Address 
Department of Dermatology, Walter Reed Army Medical Center, Washington, DC 20307, USA. 
Source 
J Am Acad Dermatol, 34(2 Pt 1):253-6 1996 Feb 

Abstract 

BACKGROUND: Confluent and reticulated papillomatosis (CRP) of Gougerot and Carteaud is an uncommon disorder of unknown cause for which a variety of treatments have been proposed.

OBJECTIVE: We attempted to evaluate the effectiveness of oral minocycline.

METHODS: Nine patients with CRP were treated with oral minocycline, 50 mg twice a day, for 6 weeks. The average follow-up period was 11 months. Recurrence rate, side effects, and effectiveness of therapy were assessed.

RESULTS: All patients except two had a 90% to 100% response to therapy. Recurrences were noted in three patients, all of whom responded to re-treatment with minocycline. None of the nine patients had an adverse reaction.

CONCLUSION: Minocycline, 50 mg twice a day, is safe and effective for CRP. 

=========================================================================
15.) Minocycline treatment for confluent and reticulated papillomatosis. 
=========================================================================
Author 
Chang SN; Kim SC; Lee SH; Lee WS 
Address 
Department of Dermatology, Yonsei University College of Medicine, Seoul, Korea. 
Source 
Cutis, 57(6):454-7 1996 Jun 

Abstract 

We report six cases of confluent and reticulated papillomatosis in which the skin lesions cleared almost completely after treatment with minocycline. Patients with confluent and reticulated papillomatosis often do not respond well to a variety of therapeutic agents.


The response of confluent and reticulated papillomatosis to minocycline was first described in 1965. Although the pharmacologic mechanisms of minocycline in confluent and reticulated papillomatosis are unknown, we suggest that it should be considered as a first-choice therapeutic agent because of its marked effectiveness. 

=========================================================================
16.) No detection of Borrelia burgdorferi-specific DNA in erythema migrans lesions after minocycline treatment. 
=========================================================================
ARTICLE SOURCE: Arch Dermatol (United States), Jun 1995, 131(6) p678-82 
AUTHOR(S): Muellegger RR; Zoechling N; Soyer HP; Hoedl S; Wienecke R; Volkenandt M; Kerl H 
AUTHOR'S ADDRESS: Department of Dermatology, Karl-Franzens University, Graz, Austria. 
PUBLICATION TYPE: JOURNAL ARTICLE 

ABSTRACT: BACKGROUND AND DESIGN: Early treatment of erythema migrans is important to prevent late complications. Minocycline possesses several attributes, making it potentially useful in the treatment of borrelial infections. In our study, minocycline was administered to 14 patients with erythema migrans. Punch biopsy specimens were obtained from the (affected) skin of all patients before and after therapy. The formalin-fixed, paraffin-embedded specimens were analyzed by polymerase chain reaction for the presence of Borrelia burgdorferi-specific DNA.

RESULTS: Polymerase chain reaction assay succeeded in amplifying B burgdorferi-specific DNA from the first biopsy specimen, obtained from the border of erythema migrans before initiating treatment, in eight (57%) of 14 patients. At the end of minocycline therapy, however, polymerase chain reaction analysis disclosed no B burgdorferi-specific DNA in any of the 14 patients. The good clinical response of our patients with erythema migrans substantiates our molecular findings.

CONCLUSIONS: The presented polymerase chain reaction data, together with the clinical outcome, indicate that minocycline may be useful for treatment of early Lyme borreliosis. 

=========================================================================
17.) Minimizing cicatricial pemphigoid orodynia with minocycline. 
=========================================================================
ARTICLE SOURCE: Br J Dermatol (England), May 1995, 132(5) p784-9 
AUTHOR(S): Poskitt L; Wojnarowska F 
AUTHOR'S ADDRESS: Dermatology Department, Amersham General Hospital, Bucks, U.K. 
PUBLICATION TYPE: JOURNAL ARTICLE 

ABSTRACT: Cicatricial pemphigoid is a rare autoimmune blistering disease of the elderly. It predominantly affects the mucosae, causing pain and scarring. the target antigen is within the lamina lucida of the basement membrane zone. Potential complications of systemic steroid and other immunosuppressive therapy have prompted trials of other means of treatment. We describe a series of seven patients treated with minocycline, six of whom derived sustained alleviation of orodynia.

Four patients developed hyperpigmentation, and two complained of gastrointestinal discomfort which necessitated cessation of minocycline. Complete steroid withdrawal was achieved in two cases. Neither the disease progression nor the response to treatment was influenced by the immunoglobulin isotype or titre. The role of minocycline as a useful adjunct to therapy is discussed. 

=========================================================================
18.) Response of atypical bullous pyoderma gangrenosum to oral minocycline hydrochloride and topical steroids. 
=========================================================================
ARTICLE SOURCE: Acta Derm Venereol (Sweden), 1990, 70(6) p538-9 
AUTHOR(S): Reynolds NJ; Peachey RD 
PUBLICATION TYPE: JOURNAL ARTICLE 

ABSTRACT: An 80-year-old Caucasian female with rheumatoid arthritis and recurrent atypical bullous pyoderma gangrenosum is described. There was no evidence of any underlying myeloproliferative disorder. Rapid healing occurred in response to oral minocycline hydrochloride and topical clobetasol propionate. 

=========================================================================
19.) Blastomycosis-like pyoderma--report of a case responsive to combination therapy utilizing minocycline and carbon dioxide laser debridement. 
=========================================================================
ARTICLE SOURCE: J Dermatol Surg Oncol (United States), Oct 1986, 12(10) p1041-4 
AUTHOR(S): Sawchuk WS; Heald PW 
PUBLICATION TYPE: JOURNAL ARTICLE 

ABSTRACT: Blastomycosis-like pyoderma is an uncommon reaction pattern to a superficial bacterial infection in persons with a variety of predisposing conditions such as chronic ethanol use and poor nutrition. We are reporting a case that initially responded poorly to previously described treatment regimens but responded well to combination treatment with carbon dioxide laser debridement and long-term minocycline. 

=========================================================================
20.) A sporotrichoid-like Mycobacterium kansasii infection of the skin treated with minocycline hydrochloride. 
=========================================================================
ARTICLE SOURCE: Br J Dermatol (England), Jul 1979, 101(1) p75-9 
AUTHOR(S): Dore N; Collins JP; Mankiewicz E 
PUBLICATION TYPE: JOURNAL ARTICLE 

ABSTRACT: A sporotrichoid-like Mycobacterium kansasii infection of the skin is reported. This is the fifth reported case in the English literature of dermatological manifestations of a M. kansasii infection and the first reported case of a response to minocycline hydrochloride therapy. 

=========================================================================
21.) Primary lymphocutaneous nocardiosis due to Nocardia otitidiscaviarum: the first case report from Japan. 
=========================================================================
ARTICLE SOURCE: J Dermatol (Japan), May 1995, 22(5) p344-7 
AUTHOR(S): Suzuki Y; Toyama K; Utsugi K; Yazawa K; Mikami Y; Fujita M; Shinkai H 
PUBLICATION TYPE: JOURNAL ARTICLE 

ABSTRACT: We report a case of lymphocutaneous syndrome caused by Nocardia otitidiscaviarum (formerly known as N. caviae) in a 78-year-old woman who underwent long-term therapy with prednisolone for bronchial asthma. Histological examination showed granulomatous reaction with multiple polymorphonuclear leukocytes and revealed a Gram positive filament in the dermis. Gram-positive, slightly acid-fast branched filaments were also found in the smear of the purulent material.

The cell wall constituents of the isolate were meso-diaminopimelic acid, arabinose, and galactose; the mycolic acid pattern of the isolate was Nocardia type. The organism decomposed xanthine and hypoxanthine, but not tyrosine or casein, which distinguished it from N. asteroides and N. brasiliensis. The skin lesions responded to minocycline and later to a combination of doxycycline and ofloxacin. This primary lymphocutaneous nocardiosis due to N. otitidiseaviarum is the first in Japan. 

=========================================================================
22.) Minocycline treatment of pulmonary nocardiosis. 
=========================================================================
ARTICLE SOURCE: JAMA (United States), Aug 19 1983, 250(7) p930-2 
AUTHOR(S): Petersen EA; Nash ML; Mammana RB; Copeland JG 
PUBLICATION TYPE: JOURNAL ARTICLE 

ABSTRACT: Minocycline hydrochloride was used to treat pulmonary infections with Nocardia asteroides in five cardiac allograft recipients. In three patients, minocycline was successfully used as the only antinocardial agent. Two other patients were found to have leukopenia after initial therapy with sulfisoxazole.

These two patients were subsequently treated with minocycline. The clinical success with minocycline in these highly immunosuppressed patients suggests that minocycline is an effective antinocardial agent. These data did not allow any conclusion regarding which drug, minocycline or sulfisoxazole, is superior in the treatment of this disease. 

=========================================================================
23.) Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group [see comments] 
=========================================================================
Author 
Tilley BC; Alarc´on GS; Heyse SP; Trentham DE; Neuner R; Kaplan DA; Clegg DO; Leisen JC; Buckley L; Cooper SM; et al 
Address 
Henry Ford Health Sciences Center, Detroit, Michigan. 
Source 
Ann Intern Med, 122(2):81-9 1995 Jan 15 

Abstract 

OBJECTIVE: To assess the safety and efficacy of minocycline in the treatment of rheumatoid arthritis.

DESIGN: A double-blind, randomized, multicenter, 48-week trial of oral minocycline (200 mg/d) or placebo. SETTING: 6 clinical centers in the United States.

PATIENTS: 219 adults with active rheumatoid arthritis who had previous limited treatment with disease-modifying drugs.

MEASUREMENTS: As the primary outcomes, 60 diarthrodial joints were examined for tenderness, and 58 joints were examined for swelling (hips excluded). Grip strength, evaluator's global assessment, morning stiffness, Modified Health Assessment Questionnaire, patient's global assessment, hematocrit, erythrocyte sedimentation rate, platelet count, and IgM rheumatoid factor levels were also assessed; radiographs of both hands and wrists were taken.

RESULTS: 109 and 110 patients were randomly assigned to receive minocycline and placebo, respectively. At entry, demographic, clinical, and laboratory measurements were similar in both groups. Most patients had mild to moderate disease activity and some evidence of destructive disease. At the week 48 visit, 79% of the minocycline group and 78% of the placebo group continued to receive the study medication. At 48 weeks, more patients in the minocycline group than in the placebo group showed improvement in joint swelling (54% and 39%) and joint tenderness (56% and 41%) (P < 0.023 for both comparisons).

The minocycline group also showed greater improvement in hematocrit, erythrocyte sedimentation rate, platelet count, and IgM rheumatoid factor levels (all P values < 0.001), and more patients receiving minocycline had laboratory values within normal ranges at 48 weeks. For the remaining outcomes, P values ranged from 0.04 to 0.76, all greater than the critical value of 0.005 (Bonferroni adjustment for multiple comparisons). The frequency of reported side effects was similar in both groups, and no serious toxicity occurred.

CONCLUSIONS: Minocycline was safe and effective for patients with mild to moderate rheumatoid arthritis. Its mechanisms of action remain to be determined. 

=========================================================================
24.) Minocycline prevents the decrease in bone mineral density and trabecular bone in ovariectomized aged rats. 
=========================================================================
Author 
Williams S; Wakisaka A; Zeng QQ; Barnes J; Martin G; Wechter WJ; Liang CT 
Address 
Gerontology Research Center, National Institute of Aging, National Institutes of Health, Baltimore, MD 21224, USA. 
Source 
Bone, 19(6):637-44 1996 Dec 

Abstract 

In the current study, we examined the effects of minocycline, on the osteopenia of ovariectomized aged rats. Old female rats were randomly divided into five groups: sham, ovariectomized control and ovariectomized treated with minocycline, 17beta-estradiol, or both agents.

Bone samples were collected 8 wk after the treatment. Ovariectomy reduced bone mineral density of the whole femur and at the condylar, distal metaphyseal and head-neck-trochanter regions 10%-19% and the loss of bone density was prevented by treatment with minocycline or 17beta-estradiol. Histomorphometric analysis of distal femur showed ovariectomy reduced the trabecular bone area, the trabecular bone number, trabecular bone thickness and increased the trabecular bone separation. The microanatomic structure of trabecular bone also showed that the number of nodes, node to node, cortical to node, node to free end was reduced by ovariectomy.

Treatment with minocycline attenuated the effect of ovariectomy on trabecular bone in aged animals. In contrast, cortical bone was not affected by ovariectomy or minocycline treatment.

The effect of minocycline on bone turnover was also examined. Minocycline increased osteoid surface, mineralizing surface, mineral apposition rate, bone formation rate and reduced eroded surface. We have therefore concluded that the modest increase in bone mineral density and the improvement in the trabecular bone status noted in minocycline treated ovariectomized aged rats is likely due to an increase in bone formation coupled with a decrease in bone resorption. 

=========================================================================
25.) Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection. 
=========================================================================
Author 
Chuang YC; Ko WC; Wang ST; Liu JW; Kuo CF; Wu JJ; Huang KY 
Address 
Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan. 
Source 
Antimicrob Agents Chemother, 42(6):1319-22 1998 Jun 

Abstract 

We conducted an in vivo study with the mouse model of Vibrio vulnificus infection to evaluate the efficacies of therapy with minocycline or cefotaxime alone and in combination. V. vulnificus was introduced subcutaneously into the area over the right thigh. The inoculum size ranged from 1.0 x 10(3) to 1.2 x 10(8) CFU from experiment to experiment but was constant for all animals in the same experiment.

Antibiotics were given intraperitoneally 2 h after the bacteria were inoculated. In experiments 1 to 4, the standard dose for humans was used to treat the infection, while in experiment 5, five times the standard dose for humans was used to treat the infection. In experiment 1, with a small inoculum of 5 x 10(3) CFU, all mice in the saline-treated control group and the cefotaxime-, minocycline-, and combined antibiotic-treated groups survived. In experiment 2, with a moderate inoculum of 1.2 x 10(5) CFU, all the mice in the three antibiotic-treated groups survived, while only two of nine mice in the control group survived. In experiment 3, with a large inoculum of 8.0 x 10(7) CFU, six of nine mice in the combined antibiotic-treated group survived, while only one of nine mice in the cefotaxime-treated group and none of the mice in the control and minocycline-treated groups survived.

In experiment 4, with a large inoculum of 1.2 x 10(8) CFU, 8 of 20 mice in the combined antibiotic-treated group survived, while none of the 20 mice in the control group, the group treated with cefotaxime alone, and the group treated with minocycline alone survived. In experiment 5, in which mice were infected with a large inoculum of 6.6 x 10(7) CFU and treated with five times the standard human dose of antibiotics, 10 of 12 mice in the combined antibiotic-treated group survived, while only 4 of 12 mice in the minocycline-treated group, 1 of 12 mice in the cefotaxime-treated group, and none of the mice in the control group survived. In experiments 3 to 5, the difference in the survival rates between the combined antibiotic-treated and minocycline-treated groups was statistically significant (P < 0.05).

These results indicate that combination therapy with cefotaxime and minocycline is distinctly more advantageous than therapy with the single antibiotic regimen for the treatment of severe experimental V. vulnificus infections. 

=========================================================================
26.) The role of minocycline in the treatment of intracranial 9L glioma. 
=========================================================================
Author 
Weingart JD; Sipos EP; Brem H 
Address 
Department of Neurological Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland. 
Source 
J Neurosurg, 82(4):635-40 1995 Apr 

Abstract 

This study was designed to explore the question of whether minocycline, a semisynthetic tetracycline shown to inhibit tumor-induced angiogenesis, could control the growth of the rat intracranial 9L gliosarcoma. Minocycline was tested alone and in combination with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in vivo. Treatment was started at the time of intracranial implantation of 9L gliosarcoma into male Fischer 344 rats, 5 days later, or after tumor resection. Minocycline was delivered locally with a controlled-release polymer or systemically by intraperitoneal injection. Systemic minocycline did not extend survival time.

Local treatment with minocycline by a controlled-release polymer implanted at the time of tumor implantation extended median survival time by 530% (p < 0.001) compared to treatment with empty polymer. When treatment was begun 5 days after tumor implantation, minocycline delivered locally or systemically had no effect on survival. However, after tumor resection, treatment with locally delivered minocycline resulted in a 43% increase in median survival time (p < 0.002) compared to treatment with empty polymer.

Treatment with a combination of minocycline delivered locally in a controlled-release polymer and systemic BCNU 5 days after tumor implantation resulted in a 93% extension of median survival time compared to BCNU alone (p < 0.002). In contrast, treatment with a combination of systemic minocycline and BCNU did not increase survival time compared to systemic BCNU alone. These results demonstrate that minocycline affects tumor growth when delivered locally and suggest that minocycline may be a clinically effective modulator of intracranial tumor growth when used in combination with a chemotherapeutic agent and surgical resection. 

=========================================================================
27.) Evaluation of the long-term efficacy and safety of locally-applied minocycline in adult periodontitis patients. 
=========================================================================
Author 
Timmerman MF; van der Weijden GA; van Steenbergen TJ; Mantel MS; de Graaff J; van der Velden U 
Address 
Department of Periodontology, Academic Centre for Dentistry, Amsterdam, The Netherlands. 
Source 
J Clin Periodontol, 23(8):707-16 1996 Aug 

Abstract 

The objectives of the present study were to establish in a long-term investigation the safety as well as the clinical and microbiological efficacy of scaling and rootplaning combined with local application of 2% minocycline hydrochloride-gel versus placebo-gel in patients with moderate to severe chronic adult periodontitis. This was an 18 months, randomized, double-blind, parallel, comparative study, in which 20 healthy patients with moderate to severe chronic periodontitis participated. At baseline, all patients received professional oral hygiene-instruction and supra- and subgingival scaling and root planing. The minocycline-gel was applied subgingivally baseline, 2 weeks, 1, 3, 6, 9 and 12 months.

Microbiological evaluation was carried out using DMDx to identify the following bacteria: Porphyromonas gingivalis, Prevotella intermedia, Actinobacillus actinomycetemcomitans, Campylobacter rectus, Fusobacterium nucleatum and Treponema denticola. In addition standard microbiological techniques were used for the detection of P. gingivalis, P. intermedia, P. micros, A. actinomycetemcomitans, C. rectus, F. nucleatum, C. albicans and Enterobacteriaceae.

Results showed a statistically significant improvement for all clinical parameters irrespective of the treatment modality. No differences were observed between test and control with regard to probing depth and attachment level. The DMDx data showed a significant reduction in both the numbers and the prevalence over the 15 months period, but no significant difference between groups.

Culture data showed that at baseline two-third were positive for P. gingivalis and P. intermedia. Analysis over the 18 month period showed no significant difference between the two treatment modalities. C. albicans and Enterobacteriaceae were detected only in small proportions at each time interval in a limited number of patients. No adverse reactions were observed during the trial period.

The present patient group responded favourably to scaling and rootplaning, but did not benefit from an effect of local of minocycline. Subgingival debridement in combination with oral hygiene instruction by itself has been shown to be effective. It remains to be studied whether local application of minocycline can be effective as an adjunct to mechanical therapy in sites that respond poorly to conventional treatment. 

=========================================================================
28.) Clinical and microbiological effects of minocycline-loaded microcapsules in adult periodontitis. 
=========================================================================
Author 
Yeom HR; Park YJ; Lee SJ; Rhyu IC; Chung CP; Nisengard RJ 
Address 
Department of Periodontology, College of Dentistry, Seoul National University, Korea. 
Source 
J Periodontol, 68(11):1102-9 1997 Nov 

Abstract 

Clinical and microbiological effects of subgingival delivery of 10% minocycline-loaded (MC), bioabsorbable microcapsules were examined in 15 adult periodontitis patients.

Patients received oral hygiene instruction 2 weeks prior to the study. At baseline (day 0) all teeth received supragingival scaling (SC); 2 quadrants received no further treatment and 1 quadrant received subgingival scaling and root planning (SRP). In the fourth quadrant, the tooth with the deepest probing sites (at least 1 site > or = 5 mm) was treated with minocycline microcapsules.

The sites were evaluated at baseline and weeks 1, 2, 4, and 6. Clinical indices included bleeding on probing (BOP), probing depths (PD), and attachment loss (AL). Microbiological evaluations included percent morphotypes by phase-contrast microscopy; cultivable anaerobic, aerobic, and black-pigmented Bacteroides (BPB); and percent Porphyromonas gingivalis, Prevotella intermedia, Eikenella corrodens, and Actinomyces viscosus by indirect immunofluorescence. In the SC + MC group, BOP, PD, and AL were significantly reduced from baseline for weeks 1 to 6. BOP in the SC + MC group was significantly reduced compared to the SRP group from weeks 2 to 6. In the SC + MC group the percent of spirochetes and motile rods decreased and the percent of cocci increased after 1 week. The increased cocci and decreased motile rods were statistically greater at weeks 4 and 6 in the SC + MC group compared to the SRP group.

This study demonstrates that local subgingival delivery of 10% minocycline-loaded microcapsules as an adjunct to scaling results in reduction in the percent sites bleeding on probing greater than scaling and root planning alone and induces a microbial response more favorable for periodontal health than scaling and
root planing. 

=========================================================================
29.) The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampin. 
=========================================================================
Author 
Raad I; Darouiche R; Hachem R; Mansouri M; Bodey GP 
Address 
Section of Infectious Diseases, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA. 
Source 
J Infect Dis, 173(2):418-24 1996 Feb 

Abstract 

The in vitro and in vivo activities of catheters coated with minocycline and rifampin and with chlorhexidine gluconate and silver sulfadiazine were evaluated. When incubated in serum at 37 degrees C, the half-life of the inhibitory activity of catheters coated with minocycline and rifampin was 25 days compared with 3 days for catheters coated with chlorhexidine gluconate and silver sulfadiazine. In a rabbit model, catheters coated with minocycline and rifampin were significantly more efficacious than catheters coated with chlorhexidine and silver sulfadiazine in preventing colonization and infection with Staphylococcus aureus (P < .05).

Catheters coated with minocycline and rifampin demonstrated broad-spectrum in vitro inhibitory activity against gram-positive bacteria, gram-negative bacteria, and Candida albicans that was significantly superior to the inhibitory activity of catheters coated with chlorhexidine gluconate and silver sulfadiazine (P < .01). Minocycline and rifampin were also highly efficacious in preventing colonization and infection in vivo. 

=========================================================================
30.) Symptomatic hepatic cysts: treatment with single-shot injection of minocycline hydrochloride. 
=========================================================================
Author 
Cellier C; Cuenod CA; Deslandes P; Auroux J; Landi B; Siauve N; Barbier JP; Frija G 
Address 
Department of Gastroenterology, Universit´e Ren´e Descartes, H^opital Laennec, Paris, France. 
Source 
Radiology, 206(1):205-9 1998 Jan 

Abstract 

PURPOSE: To assess the efficacy of percutaneous minocycline hydrochloride sclerotherapy in symptomatic hepatic cysts.

MATERIALS AND METHODS: From November 1992 to June 1994, seven of eight consecutive adults with large symptomatic hepatic cysts (diameter, 55-130 mm) were treated with a single intracystic injection of minocycline hydrochloride in an ambulatory procedure. Five patients had a solitary cyst, and two had polycystic liver disease. The target cyst was punctured under ultrasound guidance and local anesthesia with a 22-gauge Chiba needle. Half of the cyst content was aspirated before injection of 100-500 mg of minocycline hydrochloride diluted in 5-25 mL of saline. The minocycline hydrochloride was left in the cyst at the end of the procedure.

RESULTS: After a mean follow-up of 28 months (range, 24-42 months), all five patients with solitary cysts were asymptomatic and four had documented complete cyst regression; the two patients with multiple hepatic cysts showed only transient clinical improvement.

CONCLUSION: Single-shot injection of minocycline hydrochloride is an effective treatment for symptomatic solitary hepatic cysts but is less effective in polycystic liver disease. 

=========================================================================
()()()(()()()()()()()()( LO MALO / THE BAD ()()()()()()()()()()()()()()

=========================================================================
31.) Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome [see comments] 
=========================================================================
Author 
Gough A; Chapman S; Wagstaff K; Emery P; Elias E 
Address 
Department of Rheumatology, Harrogate District Hospital. 
Source 
BMJ, 312(7024):169-72 1996 Jan 20 

Abstract 

Monocycline is the most widely prescribed systemic antibiotic for acne largely because it needs to be given only once or twice a day and seems not to induce resistance. Up to April 1994 11 cases of minocycline induced systemic lupus erythematosus and 16 cases of hepatitis had been reported to the Committee on Safety of Medicines. An analysis of these cases together with seven other cases shows the severity of some of these reactions. Two patients died while taking the drug for acne and a further patient needed a liver transplant.

Acne itself can induce arthritis and is often seen in association with autoimmine liver disease, but the clinical and biochemical resolution seen after withdrawal of the drug, despite deterioration of the acne, suggests a drug reaction. In five cases re-exposure led to recurrence. Because reactions may be severe early recognition is important to aid recovery and also to avoid invasive investigations and treatments such as corticosteroids and immunosuppresants. Safer alternatives should be considered for treating acne. 

=========================================================================
32.) Minocycline and Lupuslike Syndrome in Acne Patients 
=========================================================================
Miriam C. J. M. Sturkenboom, PhD, PharmD, MSc; Christoph R. Meier, PhD, MSc; Hershel Jick, MD; Bruno H. C. Stricker, PhD, MB 
Arch Intern Med. 1999;159:493-497

Background: Recently several case reports described the association between minocycline and lupuslike syndrome. Minocycline, one of the tetracyclines, is widely used to treat acne. We aimed to examine the association of exposure to minocycline and other tetracyclines with the development of lupuslike syndrome. 

Methods: We conducted a nested case-control study in a cohort of 27,688 acne patients aged 15 to 29 years, using data automatically recorded on general practitioners' office computers in the United Kingdom. Controls were matched to cases on age, sex, and practice. The main outcome was lupuslike syndrome defined as the occurrence of polyarthritis or polyarthralgia of unknown origin,
with negative rheumatoid factor or latex agglutination test, positive or unmeasured antinuclear factor, elevated or unmeasured erythrocyte sedimentation rate, and absence of or unmeasured antinative DNA antibody levels. 

Results: We identified 29 cases and selected 152 controls. Current single use of
minocycline was associated with an 8.5-fold (95% confidence interval [CI], 2.1-35) increased risk of developing lupuslike syndrome compared with nonusers and past users of tetracyclines combined. The risk of past exposure to
any of the tetracyclines was closely similar to nonuse (relative risk, 1.3; 95% CI, 0.5-3.3). Current use of doxycycline, oxytetracycline, or tetracycline combined was associated with a 1.7-fold (95% CI, 0.4-8.1) increase of risk. The risk increased with longer use. 

Conclusion: Current use of minocycline increased the risk of developing lupuslike syndrome 8.5-fold in the cohort of young acne patients. The effect was stronger in longer-term users. However, the absolute risk of developing lupuslike syndrome seems to be relatively low. 

=========================================================================
33.) Minocycline-induced lupus. 
=========================================================================
Author 
Farver DK 
Address 
College of Pharmacy, South Dakota State University, Brookings, USA. [email protected] 
Source 
Ann Pharmacother, 31(10):1160-3 1997 Oct 

Abstract 

OBJECTIVE: To report a case of drug-induced lupus occurring 5 months after the initiation of minocycline therapy for acne.

DATA SOURCE: Case report information was obtained from the physician, patient's family, and the medical record. MEDLINE and Index Medicus were searched to obtain relevant published literature from 1966 to 1996. CASE

SUMMARY: A 14-year-old white girl developed symptoms of myalgias, arthralgias, polyarthritis, and flushed face. The antinuclear antibody test was positive. Minocycline was discontinued and the patient's condition dramatically improved within 7 days.

CONCLUSIONS: Healthcare providers should recognize early common and unusual symptoms of minocycline-induced lupus in adolescents being treated for acne. 

=========================================================================
34.) Minocycline related lupus. 
=========================================================================
Author 
Masson C; Chevailler A; Pascaretti C; Legrand E; Br´egeon C; Audran M 
Address 
Service de Rhumatologie, CHU d'Angers, France. 
Source 
J Rheumatol, 23(12):2160-1 1996 Dec 

Abstract 

The determination of a factor triggering lupus-like symptoms could yield new insights into the management of rheumatic disease. We describe a case of minocycline related lupus in a young patient positive for HLA-DR2 who was prescribed minocycline 4 times for mild acne and developed rheumatic symptoms each time. We review 8 other cases. 

=========================================================================
35.) Acute hepatitis and drug-related lupus induced by minocycline treatment. 
=========================================================================
Author 
Golstein PE; Deviere J; Cremer M 
Address 
Department of Gastroenterology, Erasmus Hospital, Universit´e Libre de Bruxelles, Belgium. 
Source 
Am J Gastroenterol, 92(1):143-6 1997 Jan 

Abstract 

Minocycline is widely prescribed for long-term treatment in acne. Major side effects are rare and include hepatitis and drug-related lupus. Hepatitis can be early and acute or late and chronic, whereas lupus presents as a tardive and insidious disease. We report a case of minocycline-induced lupus initially presenting as acute hepatitis, evolving to chronic cytolysis, in a young man treated for facial acne. 

=========================================================================
36.) Minocycline-induced pneumonitis with bilateral hilar lymphadenopathy and pleural effusion. 
=========================================================================
ARTICLE SOURCE: Intern Med (Japan), Mar 1994, 33(3) p177-9 
AUTHOR(S): Bando T; Fujimura M; Noda Y; Hirose J; Ohta G; Matsuda T 
PUBLICATION TYPE: JOURNAL ARTICLE; REVIEW (12 references); REVIEW, 

ABSTRACT: A 65-year-old man developed respiratory failure with diffuse interstitial shadow, bilateral pleural effusion, and bilateral hilar lymphadenopathy on chest X-ray and CT, after intravenous administration of minocycline. Corticosteroid therapy was effective. The findings from bronchoalveolar lavage (BAL) and transbronchial lung biopsy were compatible with eosinophilic pneumonia. Provocation test supported this diagnosis, but the lymphocyte stimulation test was negative. A review of the literature and the diagnoses of drug-induced pulmonary diseases are discussed. 

=========================================================================
37.) Comparative safety of tetracycline, minocycline, and doxycycline. 
=========================================================================
Author 
Shapiro LE; Knowles SR; Shear NH 
Address 
Department of Medicine, Sunnybrook Hospital, University of Toronto Medical School, Ontario, Canada. 
Source 
Arch Dermatol, 133(10):1224-30 1997 Oct 
Abstract 

BACKGROUND: Because minocycline can cause serious adverse events including hypersensitivity syndrome reaction (HSR), serum sicknesslike reaction (SSLR), and drug-induced lupus, a follow-up study based on a retrospective review of our Drug Safety Clinic and the Health Protection Branch databases and a literature review was conducted to determine if similar rare events are associated with tetracycline and doxycycline. Cases of isolated single organ dysfunction (SOD) attributable to the use of these antibiotics also were identified.

OBSERVATIONS: Nineteen cases of HSR due to minocycline, 2 due to tetracycline, and 1 due to doxycycline were identified. Eleven cases of SSLR due to minocycline, 3 due to tetracycline, and 2 due to doxycycline were identified. All 33 cases of drug-induced lupus were attributable to minocycline. Forty cases of SOD from minocycline, 37 cases from tetracycline, and 6 from doxycycline were detected. Hypersensitivity syndrome reaction, SSLR, and SOD occur on average within 4 weeks of therapy, whereas minocycline-induced lupus occurs on average 2 years after the initiation of therapy.

 CONCLUSIONS: Early serious events occurring during the course of tetracycline antibiotic treatment include HSR, SSLR, and SOD. Drug-induced lupus, which occurs late in the course of therapy, is reported only with minocycline. We theorize that minocycline metabolism may account for the increased frequency of serious adverse events with this drug. 

=========================================================================
38.) Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature.  =========================================================================
Author 
Knowles SR; Shapiro L; Shear NH 
Address 
Division of Clinical Pharmacology, Sunnybrook Health Science Centre, Toronto, Ontario. 
Source 
Arch Dermatol, 132(8):934-9 1996 Aug 

Abstract 

BACKGROUND: Minocycline has been reported to cause serious, albeit rare, adverse events, including serum sickness-like reaction, hypersensitivity syndrome reaction, and drug-induced lupus. A retrospective review of patients seen in our Adverse Drug Reaction Clinic as well as information obtained from the Health Protection Branch was done to identify patients with minocycline-induced reactions. In addition, the literature concerning serious reactions to minocycline was reviewed.

OBSERVATIONS: Six patients with a hypersensitivity syndrome reaction, 6 patients with a serum sickness-like reaction, and 1 patient who had symptoms consistent with drug-induced lupus were identified. A review of the literature identified 11 cases of hypersensitivity syndrome reaction, 1 case of serum sickness-like reaction, and 24 cases of drug-induced lupus. Serum sickness-like reactions occur sooner than hypersensitivity syndrome reactions (15.6 vs 23.7 days, P = .04). Drug-induced lupus occurs on average 2 years after the start of minocycline therapy.

CONCLUSIONS: Dermatologists need to be aware of the serious adverse reactions that can develop after minocycline use. In patients who may require long-term therapy with minocycline ( > 1 year), we suggest that antinuclear antibody and hepatic transaminase levels be determined at baseline. Rechallenge with minocycline or other tetracyclines is currently not recommended for patients who develop these serious reactions. 
Language 

=========================================================================
39.) [Side effects of minocycline in the treatment of acne vulgaris] 
=========================================================================
Author 
Hoefnagel JJ; van Leeuwen RL; Mattie H; Bastiaens MT 
Address 
Afd. Dermatologie, Leids Universitair Medisch Centrum, Leiden. 
Source 
Ned Tijdschr Geneeskd, 141(29):1424-7 1997 Jul 19 

Abstract 

Minocycline is the most commonly used systemic antibiotic in the long-term treatment (weeks to months) of severe acne vulgaris. Currently much attention is being paid in the Dutch and international literature to the safety of minocycline, after several reports on serious adverse events. The clinical efficacy of minocycline in the treatment of acne vulgaris is better than that of tetracycline and equal to that of doxycycline. The serious adverse events of minocycline therapy described consist of hyperpigmentation of various tissues, autoimmune disorders (systemic lupus erythematosus, autoimmune hepatitis) and serious hypersensitivity reactions (hypersensitivity syndrome reaction, pneumonitis and eosinophilia, and serum sickness-like syndrome).

In relation to the number of prescriptions, the number of serious adverse events of minocycline described is small. However, it is very important that prescribing doctors should be aware of the possibility of these adverse events occurring during long-term minocycline therapy and able to recognize the characteristic symptoms at an early stage. 

=========================================================================
40.) Serious dermatologic reactions in children. 
=========================================================================
Author 
Knowles S; Shapiro L; Shear NH 
Address 
Department of Clinical Pharmacology, Sunnybrook Health Science Centre, Toronto, Ontario, Canada. 
Source 
Curr Opin Pediatr, 9(4):388-95 1997 Aug 

Abstract 

Although serious reactions comprise only a small percentage of total adverse drug reactions, they are important in terms of morbidity and potential mortality. An update on serious dermatologic reactions in children is presented including serum sickness-like reactions due to cefaclor, hypersensitivity syndrome reactions (HSRs), and drug-induced pseudoporphyria. More detailed information on minocycline-induced reactions including drug-induced lupus and HSRs and lamotrigine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome will be discussed. 

=========================================================================
41.) Serum sickness-like syndrome associated with minocycline therapy. 
=========================================================================
ARTICLE SOURCE: Allergy (Denmark), May 1990, 45(4) p313-5 
AUTHOR(S): Puyana J; Urena V; Quirce S; Fernandez-Rivas M; Cuevas M; Fraj J 
PUBLICATION TYPE: JOURNAL ARTICLE 

ABSTRACT: A 19 year-old youth was taking oral minocycline and after 8 days he presented all four cardinal symptoms of serum sickness (urticaria, fever, lymphadenopathy and joint symptoms). C3, C4 and CH50 evolution imitate experimental serum sickness complement evolution. We exclude other causes of this syndrome. Although other hypersensitivity reactions have occurred with minocycline usage, to our knowledge serum sickness-like syndrome has not been previously reported with this drug. 

=========================================================================
42.) Minocycline-induced loss of potassium from erythrocytes: identification of a family with an augmented response. 
=========================================================================
ARTICLE SOURCE: J Infect Dis (United States), Oct 1978, 138(4) p455-62 
AUTHOR(S): Kornguth ML; Kunin CM 
PUBLICATION TYPE: JOURNAL ARTICLE 

ABSTRACT: The effect of several tetracycline antibiotics of human erythrocytes was examined because of previous findings that these drugs bind to erythrocyte membranes. Minocycline and cetocycline, two highly lipid-soluble analogues, but not tetracycline, induced loss of K+ from red blood cells. Loss of K+ increased linearly with time of incubation, concentration of minocycline, and temperature.

The effect of minocycline was inhibited by plasma and calcium. The cells from one volunteer consistently showed an augmented response to minocycline; similar findings for family members of the volunteer suggested a dominant autosomal mode of inheritance.

The only abnormality noted in the subject was mild reticulocytosis and a slightly reduced K+ content in his red blood cells. Preliminary studies did not demonstrate alterations in protein composition of his red blood cell membranes, enhanced osmotic fragility, or defects in Ca++-dependent or ouabain-sensitive (Na+-K+)-dependent adenosine triphosphatase activity. The exact site of the minocycline effect remains to be determined. 

=========================================================================
()()()()()()()()()()()()()() LO FEO / THE UGLY ()()()()()()()()()()()()
=========================================================================
43.) Minocycline-induced hyperpigmentation in leprosy. 
=========================================================================
Author 
Fleming CJ; Hunt MJ; Salisbury EL; McCarthy SW; Barnetson RS 
Address 
Department of Dermatology, Royal Prince Alfred Hospital, New South Wales, Australia. 
Source 
Br J Dermatol, 134(4):784-7 1996 Apr 

Abstract 

A 36-year-old man was treated with dapsone, rifampicin and clofazimine for borderline lepromatous leprosy. After 9 months, his leprosy plaques became progressively more red and after 23 months, the clofazimine was stopped and he was given minocycline instead.

Six weeks later, he developed blue-black pigmentation in his leprosy lesions. The histology was consistent with minocycline-induced hyperpigmentation. This is the first report of minocycline-induced pigmentation in leprosy. We suggest it is important to consider this side-effect before the administration of minocycline in leprosy, particularly if it is prescribed in place of clofazimine. 

=========================================================================
44.) Psoriatic arthritis and minocycline induced autoantibodies.
=========================================================================
Leitch DN; Haslock DI
Department of Rheumatology, South Cleveland Hospital, Middlesbrough, Cleveland.
Clin Rheumatol (BELGIUM) May 1997 16 (3) p317-8 ISSN: 0770-3198
Language: ENGLISH
Document Type: JOURNAL ARTICLE 
Journal Announcement: 9710

Subfile: INDEX MEDICUS

A case of psoriatic arthritis where diagnosis was originally complicated by the  presence of minocycline-induced auto-antibodies and hepatic dysfunction. The range  of auto-antibodies associated with minocycline includes ds DNA and SCL 70.

=========================================================================
45.) Minocycline hydrochloride hyperpigmentation complicating treatment of pyoderma gangrenosum. 
=========================================================================
ARTICLE SOURCE: J Dermatol (Japan), Dec 1994, 21(12) p965-7 
AUTHOR(S): Miralles ES; Nunez M; Perez B; Ledo A 
PUBLICATION TYPE: JOURNAL ARTICLE 

ABSTRACT: Minocycline-associated hyperpigmentation is an uncommon side effect. We report the case of a patient with pyoderma gangrenosum successfully treated with oral minocycline but complicated by marked hyperpigmentation in his pyoderma gangrenosum and acne scars.

One of the clinical forms of minocycline hyperpigmentation includes dark-blue or black macules in depressed acne scars or other sites of skin inflammation; this pattern seems to be independent of the total cumulative dose and the skin process. 

=========================================================================
46.) Minocycline-induced oral pigmentation. 
=========================================================================
ARTICLE SOURCE: J Am Acad Dermatol (United States), Feb 1994, 30(2 Pt 2)
p350-4 
AUTHOR(S): Siller GM; Tod MA; Savage NW 
PUBLICATION TYPE: JOURNAL ARTICLE 

ABSTRACT: Oral mucosal pigmentation is an infrequently reported side effect of minocycline. Two patients with minocycline deposition within teeth and bone, demonstrated by fluorescence microscopy, are described. Minocycline is the only tetracycline reported to cause discoloration of the oral mucosa.

This may be the result of deposition of an insoluble degradation product of minocycline in the underlying bone. Pigmentation is not necessarily dose-dependent and may take months or years to resolve. 

=========================================================================
47.) Nodular hyperplasia, black thyroid, and chronic minocycline ingestion in a teenager. 
=========================================================================
ARTICLE SOURCE: Arch Surg (United States), Dec 1992, 127(12) p1476-7 
AUTHOR(S): Folsom DL; Gauderer MW; Dahms WT 
PUBLICATION TYPE: JOURNAL ARTICLE; REVIEW (7 references); REVIEW OF REPORTED CASES
 
ABSTRACT: An 18-year-old man with left-lobe thyroid hemiagenesis underwent isthmectomy for management of a nodule that failed to take up radioactive iodine during a nuclear scan.

The resected tissue, which demonstrated nodular hyperplasia, and the remaining right lobe, were black. The association between deep staining and chronic minocycline ingestion was subsequently recognized. Twelve years later, the patient remained asymptomatic, suggesting that complete resection of tetracycline-stained thyroid tissue is unnecessary. 

=========================================================================
48.) Black bones following long-term minocycline treatment. 
=========================================================================
ARTICLE SOURCE: Arch Pathol Lab Med (United States), Sep 1991, 115(9) p939-41 
AUTHOR(S): Rumbak MJ; Pitcock JA; Palmieri GM; Robertson JT 
PUBLICATION TYPE: JOURNAL ARTICLE; REVIEW (16 references); REVIEW OF REPORTED CASES 

ABSTRACT: During a surgical procedure, black vertebrae were observed in a 42-year-old white woman. An undecalcified iliac crest bone biopsy specimen revealed intense fluorescence compatible with tetracycline labeling and osteoporosis. A urinary screening test was negative for amino acids.

The patient had been treated with minocycline hydrochloride (100 to 300 mg/d) for at least 6 years. Since minocycline is known to discolor many body tissues, it is likely that the black discoloration of bone in our patient was caused by the long-term intake of the antibiotic. 

=========================================================================
49.) Pigmented postacne osteoma cutis in a patient treated with minocycline: report and review of the literature. 
=========================================================================
ARTICLE SOURCE: J Am Acad Dermatol (United States), May 1991, 24(5 Pt 2)
p851-3 
AUTHOR(S): Moritz DL; Elewski B 
PUBLICATION TYPE: JOURNAL ARTICLE; REVIEW (19 references); REVIEW, TUTORIAL 

ABSTRACT: Postacne osteoma cutis is a rare complication of acne vulgaris. If it occurs during a course of tetracycline or minocycline therapy, pigmented osteomas can occur as a result of tetracycline or minocycline bone complexes. We report a case of pigmented postacne osteoma cutis that developed after extensive acne surgery and a 2- to 3-month course of minocycline.

Previously reported cases have been treated surgically, but our patient responded to 0.05% tretinoin cream, with transepidermal elimination of some osteomas. 

=====================================================================
DATA-MEDICOS/DERMAGIC-EXPRESS No (42) 17/03/99 DR. JOSE LAPENTA R. 
======================================================================
 

Produced by Dr. José Lapenta R. Dermatologist  
Maracay Estado Aragua Venezuela 1999-2025
Telf.: 04142976087 - 04127766810